Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network

Katrina Farrell, Pamela Mckay, Mike Leach
2011 Leukemia and Lymphoma  
Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-centre derived B-cell NHL than classical HL. Management of NLPHL remains controversial. In a 14-year multi-centre series, 69 cases were analysed; median follow-up was 53 months (range 11-165.) B symptoms were present in only 4.3% of patients. 81.1% of patients had stage I/II disease. Treatment was with radiotherapy (53.6 %), chemotherapy (21.7%), combined modality (17.4%)
more » ... d observation (7.2%.) 10.1% of patients relapsed and 2.9% of patients developed high-grade transformation to DLBCL. All relapses and transformations were salvageable. No patient died of their disease. The 5 yr relapse-free survival was 96.7%, transformation-free survival 98.4% and overall survival 100%. We conclude that NLPHL behaves as a distinct clinical entity, often presenting at early stage without risk factors. It has an excellent outcome. It may be possible to reduce intensity of therapy in NLPHL without affecting OS. Word Count: 148 words Farrell, McKay, Leach 2011
doi:10.3109/10428194.2011.584993 pmid:21663507 fatcat:asziv6qcync3hpat6qaj2gtexa